Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 10/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL818425 | 0.92 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL29862534 | 0.92 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL27862241 | 0.92 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6129641 | 0.91 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6129643 | 0.91 | HTR6 (0.47) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6699097 | 0.89 | HTR6 (0.45) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL818490 | 0.89 | HTR6 (0.51) | HTR6PLA2G2APLA2G10TSPO | |
| SCHEMBL29863082 | 0.89 | HTR6 (0.51) | HTR6PLA2G2APLA2G10TSPO | |
| SCHEMBL6691695 | 0.88 | HTR6 (0.44) | HTR6PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL6693682 | 0.88 | HTR6 (0.49) | HTR6PLA2G2APLA2G10TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137390-A1 | TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME IN DIABETIC PATIENTS USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITOR OR SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| EP-2154958-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | Anthera Pharmaceuticals, Inc. (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008137803-A1 | TREATMENT OF CARDIOVASCULAR DISEASE AND DYSLIPIDEMIA USING SECRETORY PHOSPHOLIPASE A2 (SPLA2) INHIBITORS AND SPLA2 INHIBITOR COMBINATION THERAPIES | ANTHERA PHARMACEUTICALS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |